Aclaris Therapeutics, Inc. (ACRS) Return on equity 2017–2025
Aclaris Therapeutics, Inc. (ACRS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-63.0%FY2025 · since FY2017: -30.4% → -63.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -63.0% | +21.9 pp |
| FY2024 | -84.9% | -28.6 pp |
| FY2023 | -56.3% | -12.3 pp |
| FY2022 | -44.0% | +2.1 pp |
| FY2021 | -46.0% | +89.5 pp |
| FY2020 | -135.5% | +95.3 pp |
| FY2019 | -230.8% | -169.1 pp |
| FY2018 | -61.7% | -31.3 pp |
| FY2017 | -30.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice